Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer

A KODK4 multicenter randomized control trial

Koji Okabayashi, Hirotoshi Hasegawa, Masahiko Watanabe, Takashi Ohishi, Akio Hisa, Yuukou Kitagawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The aim of this study was to evaluate the feasibility and conferred protection against recurrence of preoperatively administered tegafur suppositories following the intravenous and oral administration of fluoropyrimidine in a multicenter randomized control trial. Methods: Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B). The primary end points were disease-free survival (DFS) and overall survival (OS). Results: The mean follow-up periods were 80.9 ± 31.0 months in group A and 64.5 ± 28.8 months in group B. The 5-year DFS rates were 89.3% in group A and 70.3% in group B (p = 0.045), whereas the 5-year OS rates were 91.4% in group A and 73.2% in group B (p = 0.051). Furthermore, a significant difference in the cumulative distant metastatic rate was observed (group A, 7.4% vs. group B, 23.4%; p = 0.03). However, no significant difference in the cumulative local recurrence rate was seen (group A, 4.6% vs. group B, 8.2%; p = 0.68). Conclusion: Despite a relatively small sample size, preoperative tegafur suppositories might protect recurrences and improve survival rates, mainly by preventing distant metastasis. These findings suggest the utility of tegafur suppositories as an alternative neoadjuvant treatment in modern chemotherapy for colorectal cancer.

Original languageEnglish
Pages (from-to)16-23
Number of pages8
JournalOncology (Switzerland)
Volume83
Issue number1
DOIs
Publication statusPublished - 2012 Jul

Fingerprint

Tegafur
Suppositories
Adjuvant Chemotherapy
Colorectal Neoplasms
Survival Rate
Recurrence
Disease-Free Survival
Neoadjuvant Therapy
Intravenous Administration
Sample Size
Oral Administration
Neoplasm Metastasis
Drug Therapy
Survival

Keywords

  • Colorectal cancer
  • Neoadjuvant chemotherapy
  • Randomized control trial
  • Tegafur suppository

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{e6c96c0dff734fe7af316316c09a14d5,
title = "Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: A KODK4 multicenter randomized control trial",
abstract = "Objective: The aim of this study was to evaluate the feasibility and conferred protection against recurrence of preoperatively administered tegafur suppositories following the intravenous and oral administration of fluoropyrimidine in a multicenter randomized control trial. Methods: Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B). The primary end points were disease-free survival (DFS) and overall survival (OS). Results: The mean follow-up periods were 80.9 ± 31.0 months in group A and 64.5 ± 28.8 months in group B. The 5-year DFS rates were 89.3{\%} in group A and 70.3{\%} in group B (p = 0.045), whereas the 5-year OS rates were 91.4{\%} in group A and 73.2{\%} in group B (p = 0.051). Furthermore, a significant difference in the cumulative distant metastatic rate was observed (group A, 7.4{\%} vs. group B, 23.4{\%}; p = 0.03). However, no significant difference in the cumulative local recurrence rate was seen (group A, 4.6{\%} vs. group B, 8.2{\%}; p = 0.68). Conclusion: Despite a relatively small sample size, preoperative tegafur suppositories might protect recurrences and improve survival rates, mainly by preventing distant metastasis. These findings suggest the utility of tegafur suppositories as an alternative neoadjuvant treatment in modern chemotherapy for colorectal cancer.",
keywords = "Colorectal cancer, Neoadjuvant chemotherapy, Randomized control trial, Tegafur suppository",
author = "Koji Okabayashi and Hirotoshi Hasegawa and Masahiko Watanabe and Takashi Ohishi and Akio Hisa and Yuukou Kitagawa",
year = "2012",
month = "7",
doi = "10.1159/000337574",
language = "English",
volume = "83",
pages = "16--23",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer

T2 - A KODK4 multicenter randomized control trial

AU - Okabayashi, Koji

AU - Hasegawa, Hirotoshi

AU - Watanabe, Masahiko

AU - Ohishi, Takashi

AU - Hisa, Akio

AU - Kitagawa, Yuukou

PY - 2012/7

Y1 - 2012/7

N2 - Objective: The aim of this study was to evaluate the feasibility and conferred protection against recurrence of preoperatively administered tegafur suppositories following the intravenous and oral administration of fluoropyrimidine in a multicenter randomized control trial. Methods: Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B). The primary end points were disease-free survival (DFS) and overall survival (OS). Results: The mean follow-up periods were 80.9 ± 31.0 months in group A and 64.5 ± 28.8 months in group B. The 5-year DFS rates were 89.3% in group A and 70.3% in group B (p = 0.045), whereas the 5-year OS rates were 91.4% in group A and 73.2% in group B (p = 0.051). Furthermore, a significant difference in the cumulative distant metastatic rate was observed (group A, 7.4% vs. group B, 23.4%; p = 0.03). However, no significant difference in the cumulative local recurrence rate was seen (group A, 4.6% vs. group B, 8.2%; p = 0.68). Conclusion: Despite a relatively small sample size, preoperative tegafur suppositories might protect recurrences and improve survival rates, mainly by preventing distant metastasis. These findings suggest the utility of tegafur suppositories as an alternative neoadjuvant treatment in modern chemotherapy for colorectal cancer.

AB - Objective: The aim of this study was to evaluate the feasibility and conferred protection against recurrence of preoperatively administered tegafur suppositories following the intravenous and oral administration of fluoropyrimidine in a multicenter randomized control trial. Methods: Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B). The primary end points were disease-free survival (DFS) and overall survival (OS). Results: The mean follow-up periods were 80.9 ± 31.0 months in group A and 64.5 ± 28.8 months in group B. The 5-year DFS rates were 89.3% in group A and 70.3% in group B (p = 0.045), whereas the 5-year OS rates were 91.4% in group A and 73.2% in group B (p = 0.051). Furthermore, a significant difference in the cumulative distant metastatic rate was observed (group A, 7.4% vs. group B, 23.4%; p = 0.03). However, no significant difference in the cumulative local recurrence rate was seen (group A, 4.6% vs. group B, 8.2%; p = 0.68). Conclusion: Despite a relatively small sample size, preoperative tegafur suppositories might protect recurrences and improve survival rates, mainly by preventing distant metastasis. These findings suggest the utility of tegafur suppositories as an alternative neoadjuvant treatment in modern chemotherapy for colorectal cancer.

KW - Colorectal cancer

KW - Neoadjuvant chemotherapy

KW - Randomized control trial

KW - Tegafur suppository

UR - http://www.scopus.com/inward/record.url?scp=84862486438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862486438&partnerID=8YFLogxK

U2 - 10.1159/000337574

DO - 10.1159/000337574

M3 - Article

VL - 83

SP - 16

EP - 23

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 1

ER -